EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, StemCell Institute's Enterprise Value is 円5,374 Mil.
StemCell Institute's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was 円-453 Mil. Therefore, StemCell Institute's EV-to-FCF for today is -11.85.
The historical rank and industry rank for StemCell Institute's EV-to-FCF or its related term are showing as below:
TSE:7096'
s EV-to-FCF Range Over the Past 10 Years
Min: -186.17 Med: 78.56 Max: 752.68
Current: -11.85
During the past 9 years, the highest EV-to-FCF of StemCell Institute was 752.68. The lowest was -186.17. And the median was 78.56.
TSE:7096's EV-to-FCF is ranked worse than 100% of 329
companies
in the Biotechnology industry
Industry Median: 15.85
vs TSE:7096: -11.85
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
StemCell Institute (TSE:7096) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
StemCell Institute's PE Ratio (TTM) for today is calculated as:
StemCell Institute's share price for today is 円768.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. StemCell Institute's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was 円15.433.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
StemCell Institute EV-to-FCF Related Terms
StemCell Institute EV-to-FCF Historical Data
* Premium members only.
The historical data trend for StemCell Institute's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:7096 vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, StemCell Institute's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
StemCell Institute EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, StemCell Institute's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where StemCell Institute's EV-to-FCF falls into.
StemCell Institute's current Enterprise Value is 円5,374 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. StemCell Institute's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was 円-453 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
StemCell Institute (TSE:7096) has a EV-to-FCF of -11.85 as of Jul. 12, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on StemCell Institute and its competitors. According to the industry distribution chart, StemCell Institute ranks #999999 out of 329 companies in the Biotechnology industry.
Is StemCell Institute's EV-to-FCF too high?
StemCell Institute's current EV-to-FCF is -11.85. Based on the distribution chart, StemCell Institute ranks #999999 out of 329 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, StemCell Institute has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does StemCell Institute's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, StemCell Institute ranks #999999 out of 329 companies for EV-to-FCF. This places StemCell Institute in the lower half of its industry. The industry median EV-to-FCF is 15.85. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.85, based on 329 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on StemCell Institute and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. StemCell Institute's current EV-to-FCF is -11.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is StemCell Institute stock overvalued right now?
Based on GuruFocus' analysis, StemCell Institute (TSE:7096) is currently considered Possible Value Trap. The stock's GF Value™ is 円1,813.29, compared to a current price of 円768.00 — trading 57.6% below its estimated fair value. The current EV-to-FCF is -11.85. StemCell Institute's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For StemCell Institute (TSE:7096), the current EV-to-FCF is -11.85 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is StemCell Institute (TSE:7096) Overvalued in 2026?
Based on GuruFocus' analysis, StemCell Institute stock appears to be undervalued.
The current stock price of 円768.00 is trading 57.6% below its estimated GF Value™ of 円1,813.29.
GuruFocus considers StemCell Institute to be Possible Value Trap.
Key valuation signals for TSE:7096:
EV-to-FCF: -11.85
GF Value™: 円1,813.29 vs. price of 円768.00 (57.6% below fair value)
No single metric tells the full story. See the TSE:7096 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
StemCell Institute is engaged in the Cell bank business that separates and stores cord blood for regenerative medicine. Cord blood is the baby's blood contained in the umbilical cord and placenta that connects the mother and baby. In its umbilical cord blood storage business, upon receiving notification from customers who have contracted, umbilical cord blood collected at obstetric facilities throughout Japan is collected, transported to the company's cell processing center within 48 hours, and it provides a service to store cells at ultra-low temperature after separating cells from blood. The Company operates in a single segment, the cell bank business sales consist of three components: technical fees, storage fees, and other fees.
69GF Score
Get the complete analysis for TSE:7096
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7096 has been successfully added to your 
